AMIDO COMPOUNDS AS RORYT MODULATORS AND USES THEREOF

(19)

(11)

EP 3 002 008 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	24.10.2018 Bulletin 2018/43

(45)	Mention of the grant of the patent:
	15.08.2018 Bulletin 2018/33

(21)	Application number: 15188438.4

(22)	Date of filing: 11.03.2011

(51)

International Patent Classification (IPC):

A61K 31/535^(2006.01)
A61K 31/4453^(2006.01)
A61K 31/5375^(2006.01)
A61K 31/496^(2006.01)
A61K 31/404^(2006.01)
C07D 317/60^(2006.01)
C07D 405/06^(2006.01)
C07C 235/36^(2006.01)
C07D 307/52^(2006.01)
A61P 37/00^(2006.01)

A61K 31/4525^(2006.01)
A61K 31/453^(2006.01)
A61K 31/495^(2006.01)
A61K 31/40^(2006.01)
C07D 317/54^(2006.01)
C07D 403/14^(2006.01)
C07C 235/34^(2006.01)
C07D 211/16^(2006.01)
A61P 29/00^(2006.01)
A61K 31/445^(2006.01)

(54)	AMIDO COMPOUNDS AS RORYT MODULATORS AND USES THEREOF AMIDVERBINDUNGEN ALS RORYT-MODULATOREN UND VERWENDUNGEN DAVON COMPOSÉS D'AMIDO COMME MODULATEURS RORYT ET LEURS UTILISATIONS

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

11.03.2010 US 339974 P

(43)	Date of publication of application:
	06.04.2016 Bulletin 2016/14

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	11753726.6 / 2558087

(73)	Proprietors:
	New York University New York, NY 10012 (US) The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services Rockville, MD 20852-3804 (US)

(72)	Inventors:
	Littman, Dan New York, NY 1001 1 (US) Huh, Jun, R. New York, NY 10025 (US) Huang, Wenwei Rockville, Maryland (US) Huang, Ruili Rockville, MD 20850 (US) Englund, Erika, Elaine Washington, DC 20008 (US)

(74)	Representative: Teuten, Andrew John
	Sagittarius IP Three Globeside Fieldhouse Lane Marlow, Buckinghamshire SL7 1HZ Marlow, Buckinghamshire SL7 1HZ (GB)

(56)

References cited: :

WO-A2-2006/007486

NARESH KUMAR ET AL: "The Benezenesulfonamide T0901317 [N-(2,2,2-Trifluoroethyl)-N-[4-[2,2,2-trif luoro-1-hydroxy-1-(trifluoromethyl)ethyl]p henyl]-benzenesulfonamide] is a Novel Retinoic Acid Receptor-Related Orphan Receptor-alpha/gamma Inverse Agonist", MOLECULAR PHARMACOLOGY, AMERICAN SOCIETY FOR PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, US, vol. 77, no. 2, 1 February 2010 (2010-02-01), pages 228-236, XP002645391, ISSN: 0026-895X, DOI: 10.1124/MOL.109.060905 [retrieved on 2009-11-03]
KELIN LI ET AL: "Chemical Libraries via Sequential C-H Functionalization of Phenols", JOURNAL OF COMBINATORIAL CHEMISTRY, vol. 10, no. 2, 1 March 2008 (2008-03-01), pages 170-174, XP055073472, ISSN: 1520-4766, DOI: 10.1021/cc700150q
Jun R Huh: "Identification of Potent and Selective Diphenylpropanamide ROR[gamma] Inhibitors", ACS Med. Chem. Lett. 2013, 4, 6 December 2012 (2012-12-06), pages 79-84, XP055073467, DOI: 10.1021/ml300286h| Retrieved from the Internet: URL:http://pubs.acs.org/doi/pdf/10.1021/ml 300286h [retrieved on 2013-07-30]
PASHA M. KHAN ET AL: "Small molecule amides as potent ROR-[gamma] selective modulators", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 23, no. 2, 1 January 2013 (2013-01-01), pages 532-536, XP055073469, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2012.11.025

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).